только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 8 / 9
Страница 1 / 1

Список рекомендуемой литературы

  1. Абдулганиева Д.И., Беляева И.Б., Василенко А.А. и др. Место ингибитора фосфодиэстеразы-4 в комплексном лечении среднетяжелого и тяжелого псориаза и активного псориатического артрита // Научно-практическая ревматология. 2017. T. 55. № 3. C. 332–334.
  2. Абдулганиева Д.И., Бакулев А.Л., Знаменская Л.Ф. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона) // Современная ревматология. 2018. T. 12. № 3. C. 4–18.
  3. Абдулганиева Д.И., Бакулев А.Л., Знаменская Л.Ф. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона) // Альманах клинической медицины 2018. T. 46. № 6. C. 259–277.
  4. Инструкция по медицинскому применению препарата Ремикейд®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dee0585a-4511-4426-b299-39c754cc62ab (дата обращения 29.07.2022).
  5. Инструкция по медицинскому применению препарата Инфликсимаб®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f5f07b5c-c78e-4675-b487-9e040fa390bc (дата обращения 29.07.2022).
  6. Инструкция по медицинскому применению препарата Фламмэгис®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7454aae6-fea7-4c35-bba2-0f32e9413584 (дата обращения 29.07.2022).
  7. Инструкция по медицинскому применению препарата Хумира®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2037470-f733-400b-9eb5-c24f4613dba4 (дата обращения 29.07.2022).
  8. Инструкция по медицинскому применению препарата Далибра®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0c2f5cc1-c407-4981-9911-bb959dbdf2b7 (дата обращения 29.07.2022).
  9. Инструкция по медицинскому применению препарата Эксэмптия®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ca733719-5b3f-43a8-abc5-3a60ac312f6d (дата обращения 29.07.2022).
  10. Инструкция по медицинскому применению препарата Энбрел®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6deeccab-e620-4b2b-a650-4a052055fc2c (дата обращения 29.07.2022).
  11. Инструкция по медицинскому применению препарата Этанерцепт ПСК. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4fbcd769-7f43-49bd-b1e4-bdd8209d255c (дата обращения 29.07.2022).
  12. Инструкция по медицинскому применению препарата Эрелзи®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1669e025-fc37-4cea-9ac3-cc609f412cb5 (дата обращения 29.07.2022).
  13. Инструкция по медицинскому применению препарата Симпони®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ee6a721c-118d-49f3-88e4-5164ff414ade (дата обращения 29.07.2022).
  14. Инструкция по медицинскому применению препарата Симзия®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2407b390-1aec-4191-8247-0568b62ecb52 (дата обращения 29.07.2022).
  15. Инструкция по медицинскому применению препарата Стелара®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7655a82d-d4ae-4688-9b47-778197dff665 (дата обращения 29.07.2022).
  16. Инструкция по медицинскому применению препарата Козэнтикс®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0eaa0d28-60cd-4411-90a4-ca618f3600d6 (дата обращения 29.07.2022).
  17. Инструкция по медицинскому применению препарата Талс®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=094816d3-a458-4c53-be5b-e88d7d43af29 (дата обращения 29.07.2022).
  18. Инструкция по медицинскому применению препарата Эфлейра®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=923118a6-e96a-4c0b-9dea-6f1245967d5f (дата обращения 29.07.2022).
  19. Инструкция по медицинскому применению препарата Тремфея®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8afa7c58-c343-4439-9143-565d39ad59d9 (дата обращения 29.07.2022).
  20. Инструкция по медицинскому применению препарата Скайризи®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e5db55cd-2776-4042-9f18-30b4c7b51c80 (дата обращения 29.07.2022).
  21. Инструкция по медицинскому применению препарата Яквинус®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f44fa611-abc8-4428-adca-2b2dd133720b (дата обращения 29.07.2022).
  22. Инструкция по медицинскому применению препарата Тофара®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a654bd51-64af-4fe7-a7bc-9fc58e284796 (дата обращения 29.07.2022).
  23. Инструкция по медицинскому применению препарата Ранвек®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7b739124-7486-43b0-8645-a98210d71543 (дата обращения 29.07.2022).
  24. Инструкция по медицинскому применению препарата Отесла®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=52e6b3ac-da8e-4416-8b22-9f1ed7cae328 (дата обращения 29.07.2022).
  25. Инструкция по медицинскому применению препарата Дупиксент®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5cb00570-024f-44ff-9091-e43a64c01ec6 (дата обращения 29.07.2022).
  26. Инструкция по медицинскому применению препарата Ксолар®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0d0e0e14-b857-40af-9ad5-a3aab90e0f77 (дата обращения 29.07.2022).
  27. Инструкция по медицинскому применению препарата Генолар®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e090f5a1-4177-449c-a2fe-de6828b1e05c (дата обращения 29.07.2022).
  28. Кохан М.М., Соколовский Е.В., Хобейш М.М. и др. Круглый стол «Псориаз —достижения и перспективы» // Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2013. T. VIII. №27. C. 7–14.
  29. Кубанова А.А., Кубанов А.А., Знаменская Л.Ф. и др. Псориаз. В кн.: Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. М.: Деловой экспресс, 2016. 768 с.
  30. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф. и др. Индекс PASI (Psoriasis Area and Severity Index) в оценке клинических проявлений псориаза // Вестник дерматологии и венерологии. 2016. №4. C. 33–38.
  31. Кубанова А.А., Кубанов А.А., Насонов Е.Л. и др. Псориатический артрит. В кн.: Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. М.: Деловой экспресс, 2016. 768 с.
  32. Кубанов А.А., Бакулев А.Л., Карамова А.Э. и др. Клинические рекомендации. Псориаз. 2020. https://cr.minzdrav.gov.ru/schema/234_1#doc_a1 (дата обращения 29.07.2022).
  33. Кубанов А.А., Насонов Е.Л., Бакулев А.Л. и др. Клинические рекомендации. Псориаз артропатический. Псориатический артрит. 2021. https://cr.minzdrav.gov.ru/recomend/562_2 (дата обращения 29.07.2022).
  34. Кубанов А.А. и др. Клинические рекомендации. Атопический дерматит. 2021. https://cr.minzdrav.gov.ru/schema/265_2#doc_a1(дата обращения 29.07.2022).
  35. Кубанов А.А. и др. Проект. Клинические рекомендации. Крапивница. 2019. https://raaci.ru/dat/pdf/KR_urticaria_2019.pdf.
  36. Кубанов А.А., Бакулев А.Л., Самцов А.В. и др. Нетакимаб — новый ингибитор ИЛ-17а: результаты 12 недель клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом // Вестник дерматологии и венерологии. 2019. T. 95. №2. C. 15–28.
  37. Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю дерматовенерология в Российской Федерации. Итоги 2018 года // Вестник дерматологии и венерологии. 2019. T. 95. №4. C. 8–23.
  38. Мазуров В.И., Хобейш М.М., Трофимов Е.А. Принципы лечения псориаза и псориатического артрита. Методическое пособие. М.: Янссен, 2018. 60 с.
  39. Михеев Г.Н., Аравийская Е.Р., Соколовский Е.В., Холодилова Н.А. Инверсные акне: современные представления о патогенезе, клинических проявлениях и терапии // Пластическая хирургия и косметология. 2010. №3. C. 433–438.
  40. Самцов А.В., Хайрутдинов В. Р., Бакулев А.Л. и др. Эффективность и безопасность препарата BCD-085 – оригинального моноклонального антитела против интерлейкина-17 у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты II фазы международного многоцентрового сравнительного рандомизированного двойного слепого плацебо-контролируемого клинического исследования // Вестник дерматологии и венерологии. 2017. №5. C. 52–63.
  41. Хобейш М.М., Соколовский Е.В. Современные аспекты иммунопатогенеза и лечения псориаза. Правильный подход к отбору пациентов, рекомендации по скринингу и мониторингу для терапии биологическими препаратами генно-инженерного производства // Современные проблемы дерматологии, иммунологии и врачебной косметологии. 2011. T. 18. № 5. C. 56–60.
  42. Хобейш М.М., Соколовский Е.В. Рекомендации по терапии больных псориазом генно-инженерными биологическими препаратами (методические рекомендации). СПб.: Янссен, 2012. 90 с.
  43. Хобейш М.М. Иммунопатогенез псориаза и терапия в зависимости от степени тяжести и особенностей коморбидного фона // Доктор.Ру. Аллергология. Дерматология. 2013. T. 82. № 4 С. 55–60.
  44. Хобейш М.М., Бельтюкова А.С., Соколовский Е.В. Уровень основных цитокинов в крови больных псориазом // Вестник дерматовенерологии и косметологии. 2015. № 5. C. 66–72.
  45. Хобейш М.М., Сысоев К.А., Соколовский Е.В., Лапин С.В. Роль адипокинов и цитокинов в патогенезе псориаза у пациентов с сопутствующими метаболическими нарушениями // Кремлевская медицина. Клинический вестник. Дерматовенерология. 2018. № 1. C. 26–35.
  46. Хобейш М.М., Соколовский Е.В., Данилюк М.И. Успешный опыт терапии апремиластом в реальной клинической практике // Dermatology. Consilium Medicum. 2018. № 2. C. 15–19.
  47. Хобейш М.М., Соколовский Е.В., Данилюк М.И. Успешный опыт применения апремиласта: описание клинических наблюдений из реальной практики // Dermatology. Consilium Medicum. Дерматология. 2019. № 2. C. 22–25.
  48. Хобейш М.М., Шустов Д.В., Соколовский Е.В. Гидраденит суппуративный: современные представления о патогенезе, терапии и успешный опыт лечения адалимумабом // Вестник дерматологии и венерологии. 2017. № 5. C. 68–79.
  49. Antoni C., Krueger G.G., de Vlam K., Birbara et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005. Vol. 64. Р. 1150–1157.
  50. Armstrong A.W., Papp K., Kircik L. Secukinumab: review of the clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR // J. Clin. Aesth. Dermatol. 2016. Vol. 9. N. 6. Suppl. 1. P. S7–S12.
  51. Asero R., Marzano A.V., Ferrucci S., Cugno M. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria // Int. Arch. Allergy Immunol. 2017. Vol. 172. P. 40–44.
  52. Blauvelt A., Papp K.A., Griffiths C.E. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial // J. Am. Acad. Dermatol. 2017. Vol. 76. N. 3. P. 405–417.
  53. Bachelez H., van de Kerkhof P.C., Strohal R. et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial // Lancet. 2015. N. 386. Issue 9993. P. 552–561.
  54. Barker J., Hoffmann M., Wozel G. et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) // Br. J. Dermatol. 2011. Vol. 165. N. 5. P. 1109–1117.
  55. Blauvelt A., Reich K., Tsai T.F. et al. Secukunumab is superior to ustekinumab in clearing skin of subjects with moderate-to severe plaque psoriasis up to 1 year: results from the CLEAR study // J. Am. Acad. Dermatol. 2017. Vol. 76. N. e9. P. 60-69.
  56. Blauvelt A., de Bruin-Weller M., Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial // Lancet 2017. Vol. 389. Issue 10086. P. 2287–2303.
  57. Bagel J., Nia J., Hashim P.W. et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-Week CLARITY Results) // Dermatol. Ther (Heidelb). 2018. Vol. 8. N. 4. P. 571–579.
  58. Bracken S.J., Abraham S., MacLeod A.S. Autoimmune Theories of Chronic Spontaneous Urticaria // Front. Immunol. 2019. N. 10. P. 627. DOI: 10.3389/fimmu.2019.00627.
  59. Betts K., Griffith J., Friedman A. et al. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis // Curr. Med. Res. Opin. 2016. N. 32. P. 721–729.
  60. Bissonnette R., Iversen L., Sofen H. et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial //
  61. Chimenti M.S., Ortolan A., Lorenzin M. et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study // Clin. Rheumatol. 2018. Epub ahead of print. DOI:10.1007/s10067-017-3953-6.
  62. Collier F., Smith R.C., Morton C.A. Diagnosis and management of hidradenitis suppurativa // BMJ. 2013. Vol. 346. P. f 2121. DOI: 10.1136/ bmj.f 2121.
  63. Czarnowicki T., Malajian D., Shemer A. et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis // J. Allergy Clin. Immunol. 2015. Vol. 136. N. 1. P. 208–211.
  64. Coates L.C., Helliwell P.S. Treating to target in psoriatic arthritis: how to implement in clinical practice // Ann. Rheum. Dis. 2016. Vol. 75. N. 6. P. 40–43.
  65. Coates L.C., Kavanaugh A., Mease P. et al. GRAPPA 2015 Treatment Recommendations for Psoriatic Arthritis // Arthritis. Rheumatol. 2016. Vol. 68. N. 5. P. 1060–1071.
  66. Cork M.J., Eckert L., Simpson E.L. et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 // J. Dermatolog Treat. 2019. N. 9. P. 1–9.
  67. Darlenski R., Kazandjieva J., Hristakieva E., Fluhr J. Atopic dermatitis as a systemic disease // Clinics in Dermatology. 2014. N. 32. P. 409–413.
  68. de Bruin-Weller M., Thaçi D., Smith C.H. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) // Br. J. Dermatol. 2018. Vol. 178. N. 5. P. 1083–1101.
  69. Dufour D.N., Emtestam L., Jemec G.B. Hidradenitis suppurativa: a common and burdensome, yet under recognised inflammatory skin disease // Postgrad. Med. J. 2014. Vol. 90. Issue 1062. P. 216–221.
  70. Eder L., Polachek A., Rosen C. et al. The development of psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms. A Prospective Cohort Study // Arthritis. Rheumatol. 2017. Vol. 69. N. 3. P. 622–629. DOI: 10.1002/art.39973.
  71. Faustini F., Simon D., Oliveira I. et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis // Ann. Rheum. Dis. 2016. Vol. 75. P. 2068–2074.
  72. Fagerli K.M., Kearsley-Fleet L., Watson K.D. et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register // RMD Open. 2018. N. 4. P. e000596. DOI: 10.1136/ rmdopen-2017-000596.
  73. Fleming P., Drucker A.M. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials // J. Am. Acad. Dermatol. 2018. Vol. 78. N. 1. P. 62–69.
  74. Futamura M., Leshem Y.A., Thomas K.S. et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards // J. Am. Acad. Dermatol. 2016. Vol. 74. N. 2. P. 288–294.
  75. Gandhi N.A., Pirozzi G., Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases // Expert Rev. Clin. Immunol. 2017. Vol. 13. N. 5. P. 425–437.
  76. Gisondi P., Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis // Drug Des. Devel. Ther. 2016. N. 10. P. 1763–1770.
  77. Ghazanfar M.N., Thomsen S.F. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies // Case Rep. Med. 2015. Vol. 2015. P. 368053.
  78. Gladman D., Rigby W., Azevedo V.F. et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors // N. Engl. J. Med. 2017. Vol. 377. P. 1525–1536.
  79. Glintborg B., Ostergaard M., Krogh N.S. et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry // Arthritis Rheum. 2013. Vol. 65. N. 5. P. 1213–1223.
  80. Gisondi P., Fostini A.C. Foss А.I. et al. Psoriasis and the metabolic syndrome // Clin. Dermatol. 2018. N. 36. P. 21–28.
  81. Godfrey M.S., Friedman L.N. Tuberculosis and biologic therapies: anti-tumor necrosis factor-á and beyond // Clin. Chest. Med. 2019. Vol. 40. N. 4. P. 721–739.
  82. Griffiths C.E., Reich K., Lebwohl M. et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials // Lancet. 2015. Vol. 386. Issue 9993. P. 541–551.
  83. Gordon K.B., Blauvelt A., Papp K.A. et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis // N. Engl. J. Med. 2016. Vol. 375. N. 4. P. 345–356.
  84. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial // J. Am. Acad. Dermatol. 2004. Vol. 51. N. 4. P. 534–542.
  85. Gottlieb A., Blauvelt A., Thaci D. et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) // J. Am. Acad. Dermatol. 2018. Vol. 79. N. 2. P. 302–314.
  86. Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial // Lancet. 2009. Vol. 373. P. 633–640. DOI: 10.1016/S0140-6736(09)60140-9.
  87. Gulliver W., Tzellos T., Zouboulis CC. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa // Rev. Endocr. Metab. Disord. 2016.
  88. Gonz_alez-Medina M., Curto-Barredo L., Labrador-Horrillo M. et al. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases // J. Eur. Acad. Dermatol Venereol 2017. Vol. 31. P. e245–e246.
  89. Hawro T., Ohanyan T., Schoepke N. et al. Comparison and interpretability of the available urticaria activity scores // Allergy 2017. Vol. 7. P. 251–255.
  90. Hyrich K.L., Verstappen S.M. Biologic therapies and pregnancy: the story so far // Rheumatol. 2014. Vol. 53. N. 8. P. 1377–1385. DOI:10.1093/rheumatology/ket409.
  91. Iannone F., Lopriore S., Bucci R. et al. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings // J. Rheumatol. 2016. N. 43. P. 911–917.
  92. Jani M., Macphie E., Rao C. et al. Effectiveness of switching between biologics in psoriatic arthritis — results of a large regional survey // Clin. Med. (London) 2014. Vol. 14. N. 1. P. 95–96.
  93. Jemec G.B.E. Clinical practice: hidradenitis suppurativa // N. Engl. J. Med. 2012. Vol. 366. P. 158–164.
  94. Jemec G.B.E., Gottlieb A., Forman S. et al. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomized placebo-controlled trial // Ann. Meet. Am. Acad. Dermatol. 2015. N. 73.
  95. Kaplan A., Ledford D., Ashby M. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy // J. Allergy. Clin. Immunol. 2013. N. 132. P. 101–109.
  96. Kavanaugh A., Puig L., Gottlieb A.B. et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) // Ann. Rheum. Dis. 2016. Vol. 75. P. 1984–1988. DOI: 10.1136/annrheumdis-2015-209068.
  97. Kavanaugh A., McInnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study // Arthritis Rheum. 2009. Vol. 60. N. 4. P. 976–986. DOI: 10.1002/art.24403.
  98. Kavanaugh A., Mease P., Gomez-Reino J. et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor // Ann. Rheum. Dis. 2014. Vol. 73. P. 1020–1026.
  99. Кhobeysh М., Sysoev K., Sokolovskiy E., Lapin S. Adipokines and cytokines in the pathogenesis of psoriasis and metabolic disorders EULAR 2018. Amsterdam: The Abstract Book. AB0070. DOI: 10.1136/annrheumdis-2018- eular. 5684.
  100. Kimball A.B., Gordon K.B., Fakharzadeh S. et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years // Br. J. Dermatol. 2012. Vol. 166. N. 4. P. 861–872.
  101. Kimball A, Jemec G.B.E., Gu Y. et al. A novel hidradenitis suppurativa efficacy variable, HiSCR (Hidradenitis Suppurativa Clinical Response), is responsive to change with adalimumab therapy: results of a phase 2 study // Ann. Meet. J. Acad. Am. Dermatol. 2013. N. 71.
  102. Kimball A. et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment // BJD. 2014. Vol. 171. N. 1. P. 434–442.
  103. Kimball A.B., Jemec G., Armstrong A. et al. Evaluating optimal medium-term dosing strategy for adalimumab in patients with moderate-to-severe hidradenitis suppurativa based on analysis of integrated results from the PIONEER I & II phase 3, randomized, placebo-controlled trials. Poster presented at: 23rd World Congress of Dermatology (WCD). 2014. Vancouver, Canada. Abstract 3079375.
  104. Kimball A.B., Zouboulis C.C., Armstrong A.W. et al. Safety and efficacy of adalimumab in patients with moderate to severe hidradenitis suppurativa: results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial // Ann. Meet. Am. Acad. Dermatol. 2015. N. 73.
  105. Klein M., Jarosova K., Forejtova S. et al. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection treated with tumor necrosis factor alpha blocing agents // Clin. Exper. Rheumatol. 2013. N. 31. P. 111–117.
  106. Kolkhir P., Church M.K., Weller K. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know // J. Allergy Clin. Immunol. 2017. Vol. 139. N. 6. P. 1772–1781.
  107. Kuo C.M., Tung T.H., Wang S.H., Chi C.C. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials // J. Eur. Acad. Dermatol. Venereol. 2018. Vol. 32. N. 3. P. 355–362.
  108. Lecluse L.L., Piskin G., Mekkes J.R. et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions // Br. J. Dermatol. 2008. Vol. 159. P. 527–536.
  109. Leonardi C.L., Kimball A.B., Papp K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) // Lancet. 2008. Vol. 371. Issue9625. P. 1665–1674.
  110. Leonardi C., Maari C., Philipp S. et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study // J. Am. Acad. Dermatol. 2018. Vol. 79. N. 5. P. 824–830.
  111. Langley R.G., Tsai T.F., Flavin S. et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial // Br. J. Dermatol. 2018. Vol. 178. N. 1. P. 114–123.
  112. Maneiro J.R., Salgado E. et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systemic review and meta-analysis of randomized controlled trials and long-term extension studies // Rheumatol. (Oxford) 2014. Vol. 53. P. 1872–1875. DOI: 10.1093/rheumatology/keu172.
  113. Mariette X., Förger F., Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study // Ann. Rheum. Dis. 2018. Vol. 77. P. 228–233.
  114. Mariette X., Vencovsky J., Lortholary O. et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region // RMD Open. 2015. Vol. 1. N. 1. P. e000044. DOI: 10.1136/rmdopen-2014-000044.
  115. Marchesoni A., Oliveri I., Salvarani C. et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology // Clin. Experimen Rheumatol. 2017. Vol. 35. P. 991–1010.
  116. Margesson L.J., Danby F.W. Hidradenitis suppurativa // Best Pract. Res. Clin. Obstet. Gynaecol. 2014. Vol. 28. N. 7. P. 1013–1027.
  117. Magerl M., Altrichter S., Borzova E. et al. The definition, diagnostic testing, and management of chronic inducible urticarias — the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision // Allergy 2016. Vol. 71. P. 780–802.
  118. Matsunaga M.C., Yamauchi P.S. IL-4 and IL-13 Inhibition in Atopic Dermatitis // J. Drugs Dermatol. 2016. Vol. 15. N. 8. P. 925–929.
  119. Maurer M., Church M.K., Goncalo M. et al. Management and treatment of chronic urticaria (CU) // JEADV. 2015. Vol. 29. Suppl. 3. P. 16–32.
  120. Maurer M., Altrichter S., Schmetzer O. et al. Immunoglobulin E‐mediated autoimmunity // Fronti Immunol. 2018. N. 9. P. 689.
  121. Maurer M., Rosen K., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria // N. Engl. J. Med. 2013. Vol. 368. P. 924–935.
  122. Maurer M., Metz M., Brehler R. et al. Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence // J. Allergy Clin. Immunol. 2017.
  123. Tharp M.D., Bernstein J.A., Kavati A. et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of «Real-world» // Evidence Dermatol. 2019. Vol. 155. N. 1. P. 29–38.
  124. McInnes I., Kavanaugh A., Gottlieb A. et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study // Ann. Rheum. Dis. 2012. Vol. 71. P. 107. DOI: 10.1016/S0140-6736(13)60594-2.
  125. McInnes I., Kavanaugh A., Gottlieb A. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial // Lancet. 2013. Vol. 382. Issue 9894. P. 780–789. DOI: 10.1016/S0140-6736(13)60594-2.
  126. McInnes I.B., Mease P.J., Kirkham B. et al. Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase-3 trial // Lancet. 2015. Vol. 386. Issue 9999. P. 1137–1146.
  127. Mease P., Hall S., FitzGerald O. et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis // N. Engl. J. Med. 2017. Vol. 377. P. 1537–1550. DOI: 10.1056/NEJMoa1615975.
  128. Mease P.J., Kavanaugh A., Reimold A. et al. Secukinumab Provides Sustained Improvements in the Signs and Symptomsin Psoriatic Arthritis: Final 5 Year efficacy and safety results from a phase 3 trial [abstract] // Arthritis Rheumatol. 2018. Vol. 70. Suppl. 10.
  129. Mease P., Adebajo A., Gladman D. et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3 randomized, controlled trials // Ann. Rheum. Dis. 2015. Vol. 74. Suppl. 2. P. 355–356.
  130. Menter A., Gottlieb A., Fedman S. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics // J. Am. Acad. Dermatol. 2008. Vol. 58. P. 826–850. DOI: 10.1016/j.jaad.2008.02.039.
  131. Menter A., Strober B.E., Kaplan D.H. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics // J. Am. Acad. Dermatol. 2019. Vol. 80. N. 4. P. 1029–1072.
  132. Mlynek A., Zalewska-Janowska A., Martus P. et al. How to assess disease activity in patients with chronic urticaria? // Allergy 2008. Vol. 63. P. 777–780.
  133. Mozeika E., Pilmane M., Nürnberg B.M., Jemec G.B. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa // Acta Derm. Venereol. 2013. Vol. 93. P. 301–304.
  134. Namazy J., Cabana M.D., Scheuerle A.E. et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy // J. Allergy Clin. Immunol. 2015. Vol. 135. P. 407–412.
  135. Napolitano M., Megna M., Timoshchuk E.A. et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment // Clin.Cosm. Invest. Dermatol. 2017. N. 10. P. 105–115.
  136. Nash P., Ohson K., Walsh J. et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, Randomized, Controlled Trial (ACTIVE) // Ann. Rheum. Dis. 2018. Vol. 77. P. 690–698.
  137. Navarro R., Vilarrasa E., Herranz P. et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicenter study in a clinical setting // BJD 2013. Vol. 168. P. 609–616.
  138. Nazary M., van der Zee H.H., Prens E.P. et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa // Euro J. Pharmacol. 2011. Vol. 672. N. 1–3. P. 1–8.
  139. Oranje A.P., Stalder J.F., Taieb A. et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child // Pediatr Allergy Immunol. 1997. N. 8. P. 28–34.
  140. Ortiz N.E., Nijhawan R.I., Weinberg J.M. Acitretin // Dermatol Ther 2013. Vol. 26. N. 5. P. 390–399.
  141. Paller A.S., Siegfried E.C., Langley R.G. et al. Etanercept treatment for children and adolescents with plaque psoriasis // N. Engl. J. Med. 2008. Vol. 358. N. 3. P. 241–251.
  142. Papp K., Reich K., Leonardi C.L. et al. Apremilast, an oral phosphodi­esterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1) // J. Am. Acad. Dermatol. 2015. Vol. 73. P. 37–49.
  143. Papp K.A., Krueger J.G., Feldman S.R. et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study // J. Am. Acad. Dermatol. 2016. Vol. 74. N. 5. P. 841–850.
  144. Papp K.A., Menter M.A., Abe M. et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials // Br. J. Dermatol. 2015. Vol. 173. N. 4. P. 949–961.
  145. Papp K.A., Langley R.G., Lebwohl M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) // Lancet 2008. Vol. 371. Issue 9625. P. 1675–1684.
  146. Papp K.A., Griffiths C.E., Gordon K. et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up // Br. J. Dermatol. 2013. Vol. 168. N. 4. P. 844–854.
  147. Paul C., Cather J., Gooderham M. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) // Br. J. Dermatol. 2015. Vol. 173. N. 6. P. 1387–1399.
  148. Paul C., Reich K., Gottlieb A.B. et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial // J. Eur. Acad. Dermatol. Venerol. 2014. Vol. 28. P. 1670–1675.
  149. Pavelka K., Kivitz A., Dokoupilova E. et al. Efficacy, safety, and tolerability of sekukinumab in patients with ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 // Arthritis. Res. Ther. 2017. Vol. 19. N. 1. P. 285. Doi: 10.1186/s13075-017-1490-y.
  150. Pink A.E., Simpson M.A., Desai N. et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa) // J. Invest. Dermatol. 2012. Vol. 132. P. 2459–2461.
  151. Ravindran V., Scott D.L., Choy E.H. A systematic review and metaanalysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis // Ann. Rheum. Dis. 2008. Vol. 67. P. 855–859.
  152. Reich K., Papp K.A., Armstrong A.W. et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies // Br. J. Dermatol. 2019. Vol. 180. N. 5. P. 1039–1049.
  153. Reich K., Armstrong A.W., Langley R.G. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial // Lancet. 2019. Vol. 394. Issue 10201. P. 831–839.
  154. Reich K., Pinter A., Lacour J.P. et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study // Br. J. Dermatol. 2017. Vol. 177. N. 4. P. 1014–1023.
  155. Reich K., Leonardi C., Lebwohl M. et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER3) // J. Dermatolog. Treat. 2017. Vol. 28. N. 4. P. 282–287.
  156. Reich K., Nestle F.O., Papp K. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial // Lancet. 2005. Vol. 366. Issue 9494. P. 1367–1374.
  157. Reed M., Crosbie D. Apremilast in the Treatment of Psoriatic Arthritis: a perspective review // Ther. Adv. Musculoskel. Dis. 2017. Vol. 9. N. 2. P. 45–53.
  158. Reid V., Castelino M., Parker B. et al. Biological pathways for ankylosing spondylitis (including non-radiographic axial spondyloarthritis — AS) and psoriatic arthritis PsA. GMMMG. NHS. 2018.
  159. Revuz J.E., Canoui-Poitrine F., Wolkenstein P. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies // J. Am. Acad. Dermatol. 2008. Vol. 59. P. 596–601.
  160. Ritchlin C., Gottlieb A., McInnes I. et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study // Arthritis Rheum. 2012. Vol. 64. P. 1080–1081. DOI: 10.1136/annrheumdis-2013-204655.
  161. Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II // J. Am. Acad. Dermatol. 2010. Vol. 63. N. 6. P. 949–972.
  162. Ryan C., Menter A., Guenther L. et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis // Br. J. Dermatol. 2018. Vol. 179. N. 4. P. 844–852.
  163. Saad A.A., Ashcroft D.M., Watson K.D. et al. Eficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register // Rheumatol. 2010. Vol. 49. N. 4. P. 697–705. DOI: 10.1093/rheumatology/kep423.
  164. Saini S.S., Bindslev-Jensen C., Maurer M. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study // J. Invest. Dermatol. 2015. Vol. 135. P. 67–75.
  165. Schmitt J., Schwarz K., Baurecht H. et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes // J. Allergy Clin. Immunol. 2016. Vol. 137. N. 1. P. 130–136.
  166. Simpson E.L., Bieber T., Guttman-Yassky E. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis // N. Engl. J. Med. 2016. Vol. 375. N. 24. P. 2335–2348.
  167. Snast I., Reiter O., Hodak E. et al. Are biologics efficacious in atopic dermatitis? asystematic review and meta-analysis // Am. J. Clin. Dermatol. 2018. Vol. 19. N. 2. P. 145–165.
  168. Souto A., Maneiro J.R., Salgado E. et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systemic review and meta-analysis of randomized controlled trials and long-term extension studies// Rheumatol. (Oxford) 2014. Vol. 53. P. 1872–1875. DOI: 10.1093/rheumatology/keu172.
  169. Sroka-Tomaszewska J., Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis // Int. J. Mol. Sci. 2021. Vol. 22. N. 8. P. 4130. DOI:10.3390/ijms22084130.
  170. Sterry W., Ortonne J.P., Kirkham B. et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial // BMJ. 2010. Vol. 340. P. 147.
  171. Tamagawa-Mineoka R., Katoh N. Atopic Dermatitis: Identification and Management of Complicating Factors // Int. J. Mol. Sci. 2020. Vol. 21. N. 8. P. 2671.
  172. Tan J.Y., Li S., Yang K. et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis // J. Dermatolog. Treat. 2011. Vol. 22. N. 6. P. 323–336.
  173. Thaci D., Blauvelt A., Reich K. et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial // Am. Acad. Dermatol. 2015. Vol. 73. N. 3. P. 400–409.
  174. Thaçi D., Simpson E., Deleuran M. et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) // J. Dermatol. Sci. 2019. Vol. 94. N. 2. P. 266–275.
  175. Tharp M.D., Bernstein J.A., Kavati A. et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of «Real-world» // Evidence Dermatol. 2019. Vol. 155. N. 1. P. 29–38.
  176. Tian F., Chen Z., Xu T. et al. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis // J. Int. Med. Res. 2019. Vol. 47. N. 6. P. 2342–2350.
  177. Ungprasert P., Thongprayoon C., Davis J. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis // Clin. Rheumatol. 2016 35. P. 1795–1803.
  178. van de Kerkhof P., Guenther L., Gottlieb A.B. et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3 // J. Eur. Acad. Dermatol. Venereol. 2017. Vol. 31. N. 3. P. 477–482.
  179. van der Zee H.H., Laman J.D., Boer J., Prens E.P. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments // Exper. Dermatol. 2012. Vol. 21. N. 10. P. 735–739.
  180. Vazquez B.G., Alikhan A., Weaver A.L. et al. Incidence of hidradenitis suppurativa and associated factors: a populationbased study of Olmsted County, Minnesota // J. Invest. Dermatol. 2013. Vol. 133. P. 97–103.
  181. Wang F.P., Tang X.J., Wei C.Q. et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis // J. Dermatol. Sci. 2018. Vol. 90. N. 2. P. 190–198.
  182. Wells A.F., Edwards C.J., Kivitz A.J. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebocontrolled PALACE 4 trial // Rheumatol. 2018. N. 57. P. 12531263. DOI: 10.1093/rheumatology/key032.
  183. Werfel T., Allam J.P., Biedermann T. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis // J. Allergy Clin. Immunol 2016. Vol. 138. P. 336–349.
  184. West J., Ogston S., Foerster J. Safety and efficacy of methotrexate in psoriasis: ameta-analysis of published trials // PLoS ONE. 2016. Vol. 11. N. 5. P. e0153740.
  185. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I // J. Eur. Acad. Dermatol. Venereol. 2018. Vol. 32. N. 5. P. 657–682.
  186. Zhao Z.T., Ji C.M., Yu W.J. et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials // J. Allergy Clin. Immunol 2016. N. 137. P. 1742–1750.
  187. Zouboulis C.C., Desai N., Emtestam L. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa // J. Eur. Acad. Dermatol. Venereol. 2015. Vol. 29. N. 4. P. 619–644.
  188. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticarial // Allergy. 2018. Vol. 73. P. 1393–1414. DOI: 10.1111/ all.13397.

Для продолжения работы требуется вход / регистрация